

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not yet known
				Filing Date	Herewith
				First Named Inventor	Madaline CHIRICA
				Art Unit	Not yet known 1647
				Examiner Name	Not yet known J. Seharaseyon
Sheet	1	of	3	Attorney Docket Number	DX01074B1K

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
JS	AA	WO 01/18051	03-15-2001	OPPMANN, et al.	pages 43-50	

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	02/07/2007
-----------------------	---------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	Not yet known
				Filing Date	Herewith
				First Named Inventor	Madaline CHIRICA
				Art Unit	Not yet known 1647
				Examiner Name	Not yet known J. Seharaseyon
Sheet	2	of	3	Attorney Docket Number	DX01074B1K

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JS	AB	S. AGGARWAL, <i>et al.</i> , <u>J. Biol. Chem.</u> 278(3):1910-1914, January 17, 2003. "Interleukin-23 promotes a distinct CD4 T cell activation state characterized by production of interleukin-17"	
	AC	KIM E. BARRETT, <u>Baillieres Clin. Gastroenterol.</u> , 10(1):1-15, March 1996. "Cytokines: sources, receptors and signalling"	
	AD	J. FERNANDO BAZAN, <i>et al.</i> , <u>Nature</u> , 379:591, February 15, 1996. "A newly defined interleukin-1?"	
	AE	CHRISTOPH BECKER, <i>et al.</i> , <u>J. Clin. Invest.</u> 112:693-706, September 2003. "Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells."	
	AF	J. BRISCOE, <i>et al.</i> , <u>Philos. Trans. R. Soc. Lond. B Biol. Sci.</u> 351(1336):167-71, February 29, 1996. "JAKs, STATs and signal transduction in response to the interferons and other cytokines"	
	AG	IRWIN M. CHAIKEN and WILLIAM V. WILLIAMS, <u>Trends Biotechnol.</u> , 14(10):369-75, October 1996. "Identifying structure-function relationships in four-helix bundle cytokines: towards de novo mimetics design"	
	AH	ANDREA M. COOPER, <i>et al.</i> , <u>J. Immunol.</u> , 168:1322-1327, 2002. "Mice lacking bioactive IL-12 can generated protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present"	
	AI	DANIEL J. CUA, <i>et al.</i> , <u>Nature</u> , 421:744-748, February 13, 2003. "Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain"	
	AJ	THOMAS J. GONDA and RICHARD J. D'ANDREA, <u>Blood</u> , 89(2):355-369, January 15, 1997. "Activating mutations in cytokine receptors: implications for receptor function and role in disease"	
	AK	KYLE I. HAPPEL, <i>et al.</i> , <u>J. Immunol.</u> , 170:4432-4436, 2003. "Cutting edge: roles of toll-like receptor 4 and IL-23 in IL-17 expression in response to <i>Klebsiella pneumoniae</i> infection"	
	AL	PETER C. HEINRICH, <i>et al.</i> , <u>Biochem. J.</u> , 334 (Pt 2):297-314, September 1, 1998. "Interleukin 6-type cytokine signalling through the gp130/Jak/STAT pathway"	
	AM	JEFFREY M. HERZ, <i>et al.</i> , <u>J. Recept. Signal Transduct. Res.</u> , 17(5):671-776, Sept. 1997. "Molecular approaches to receptors as targets for drug discovery"	
	AN	M. HIBI, <i>et al.</i> , <u>GenBank</u> , Accession No. M57230, January 6, 1995. "Definition: Human membrane glycoprotein gp130 mRNA, complete cds."	
	AO	CHRISTOPH HOLSCHER, <i>et al.</i> , <u>J. Immunol.</u> , 167:6957-6966, 2001. "A protective and agonistic function of IL-12p40 in mycobacterial infection"	

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	02/07/2007
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	Not yet known
				Filing Date	Herewith
				First Named Inventor	Madaline CHIRICA
				Art Unit	Not yet known 1647
				Examiner Name	Not yet known J. Seharaseyon
Sheet	3	of	3	Attorney Docket Number	DX01074K1B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JS	AP	JAMES N. IHLE, <i>et al.</i> , <u>Stem Cells</u> , 15 (Suppl 1):105-11, 1997. "Jaks and Stats in cytokine signaling"	
	AQ	DAVID E. LEVY, <u>Cytokine Growth Factor Rev.</u> , 8(1):81-90, March 1997. "The house that JAK/STAT built"	
	AR	TAMARA KRAJINA, <i>et al.</i> , <u>Eur. J. Immunol.</u> , 33:1073-1083, 2003. "Colonic lamina propria dendritic cells in mice with CD4 ⁺ T cell-induced colitis"	
	AS	S. LOK, <i>et al.</i> , <u>Database EMBL Online!</u> , Accession Number, AF178684, September 10, 1999. "Definition: Homo sapiens class I cytokine receptor (zcytor5) mRNA, complete cds"	
	AT	CHRISTI PARHAM, <i>et al.</i> , <u>J. Immunol.</u> , 168:5699-5708, 2002. "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rb1 and a novel cytokine receptor subunit, IL-23R"	
	AU	NEELA PATEL, <i>et al.</i> , <u>J. Biol. Chem.</u> , 271(48):30386-30391, November 29, 1996. "Functional replacement of cytokine receptor extracellular domains by leucine zippers"	
	AV	DAVID H. PRESKY, <i>et al.</i> , <u>Proc. Natl. Acad. Sci. USA</u> , 93:14002-14007, November 1996. "A functional interleukin 12 receptor complex is composed of two b-type cytokine receptor subunits"	
	AW	D.H. PRESKY, <i>et al.</i> , <u>GenBank</u> , Accession No. U64198, November 28, 2000. "Definition: Human IL-12 receptor beta2 mRNA, complete cds."	
	AX	OLLI SILVENNOINEN, <i>et al.</i> , <u>APMIS</u> , 105(7):497-509, July 1997. "Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors"	
	AY	HOLM H. UHLIG and FIONA POWRIE, <u>J. Clin. Invest.</u> , 112(5):648-651, September 2003. "Dendritic cells and the intestinal bacterial flora: a role for localized mucosal immune responses."	
	AZ	M. T. WIEKOWSKI, <i>et al.</i> , <u>J. Immunol.</u> , 166:7563-7570 (2001). "Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death"	
	BA	R.H. WATERSTON, <u>Database EMBL Online!</u> , Accession Number, AC26054, March 20, 2000. "Definition: Homo sapiens chromosome 1 clone RP11-131015, working draft sequence, 26 unordered pieces."	
	BB	LINDA A. WINSTON and TONY HUNTER, <u>Current Biology</u> , 6(6):668-671, June 1, 1996. "Intracellular signalling: Putting JAKs on the kinase MAP"	

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	02/07/2007
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY: DOCKET NO.: DX01074B1K		APPLICATION NO.: 10/720,026	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Madaline Chirica et al.			
				FILING DATE: November 21, 2003		GROUP: 1647 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
JS	AA	6,495,667 B1	12/17/02	J. Fernando Bazan	530	389.2	Apr. 25, 2000
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO
JS	AL	WO 01/18051	03/15/01	WIPO	C07K	14/54	x
JS	AM	WO 01/85790	11/15/01	WIPO	C07K	14/705	x
	AN						
	AO						
	AP						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AQ	Patent Cooperation Treaty International Search Report for application no. PCT/US2004/038886					
	AR						
	AS						
	AT						
	AU						
	AV						
EXAMINER <u>Jegatheesan Seharaseyon/</u>				DATE CONSIDERED <u>02/07/2007</u>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							